Matt Abernethy Neurocrine Biosciences Inc (NBIX) insider trading activity

Matt Abernethy is Chief Financial Officer of NEUROCRINE BIOSCIENCES INC. Currently has a direct ownership of 35,810 shares of NBIX, which is worth approximately $4.25 Million. The most recent transaction as insider was on Feb 13, 2025, when has been sold 2,558 shares (Common Stock) at a price of $116.86 per share, resulting in proceeds of $298,927. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.8K

13.58% 3M change

13.58% 12M change

Total Value Held $4.25 Million

MATT ABERNETHY Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 13 2025	SELL Open market or private sale	$298,927 $116.86 p/Share	2,558 Reduced 6.67%	35,810 Common Stock
Feb 13 2025	BUY Exercise of conversion of derivative security	-	4,807 Added 11.49%	37,016 Common Stock
Feb 10 2025	SELL Open market or private sale	$115,904 $118.27 p/Share	980 Reduced 2.84%	33,561 Common Stock
Feb 08 2025	BUY Exercise of conversion of derivative security	-	1,860 Added 5.11%	34,541 Common Stock
Jan 31 2025	SELL Open market or private sale	$196,132 $152.87 p/Share	1,283 Reduced 3.78%	32,681 Common Stock
Jan 31 2025	BUY Exercise of conversion of derivative security	-	2,436 Added 6.69%	33,964 Common Stock
Aug 13 2024	SELL Open market or private sale	$2,120,358 $150.38 p/Share	14,100 Reduced 30.9%	31,528 Common Stock
Aug 13 2024	BUY Exercise of conversion of derivative security	$1,037,759 $73.6 p/Share	14,100 Added 23.61%	45,628 Common Stock
Jul 16 2024	SELL Open market or private sale	$135,036 $150.04 p/Share	900 Reduced 2.78%	31,528 Common Stock
Jul 16 2024	BUY Exercise of conversion of derivative security	$66,240 $73.6 p/Share	900 Added 2.7%	32,428 Common Stock
May 15 2024	SELL Open market or private sale	$2,103,600 $140.24 p/Share	15,000 Reduced 32.24%	31,528 Common Stock
May 15 2024	BUY Exercise of conversion of derivative security	$1,104,000 $73.6 p/Share	15,000 Added 24.38%	46,528 Common Stock
May 14 2024	SELL Open market or private sale	$2,034,900 $135.66 p/Share	15,000 Reduced 32.24%	31,528 Common Stock
May 14 2024	BUY Exercise of conversion of derivative security	$1,104,000 $73.6 p/Share	15,000 Added 24.38%	46,528 Common Stock
Feb 13 2024	SELL Open market or private sale	$179,613 $132.85 p/Share	1,352 Reduced 4.11%	31,528 Common Stock
Feb 08 2024	SELL Open market or private sale	$131,525 $134.21 p/Share	980 Reduced 3.13%	30,314 Common Stock
Feb 06 2024	SELL Open market or private sale	$182,003 $142.19 p/Share	1,280 Reduced 4.17%	29,434 Common Stock
Jan 31 2024	SELL Open market or private sale	$180,543 $140.72 p/Share	1,283 Reduced 4.34%	28,284 Common Stock
Aug 21 2023	SELL Open market or private sale	$228,955 $107.39 p/Share	2,132 Reduced 7.29%	27,131 Common Stock
Feb 08 2023	SELL Open market or private sale	$102,106 $104.19 p/Share	980 Reduced 3.74%	25,213 Common Stock
Feb 07 2023	SELL Open market or private sale	$2,695,460 $102.38 p/Share	26,328 Reduced 51.97%	24,333 Common Stock
Feb 06 2023	SELL Open market or private sale	$135,257 $105.67 p/Share	1,280 Reduced 5.38%	22,507 Common Stock
Jan 31 2023	SELL Open market or private sale	$141,104 $109.98 p/Share	1,283 Reduced 5.67%	21,357 Common Stock
Feb 08 2022	SELL Open market or private sale	$78,057 $79.65 p/Share	980 Reduced 4.63%	20,204 Common Stock
Feb 07 2022	SELL Open market or private sale	$267,415 $80.79 p/Share	3,310 Reduced 14.62%	19,325 Common Stock

Matt Abernethy

Chief Financial Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells NBIX shares.

Notify only if

Value

Insider Trading

Get notified when an Neurocrine Biosciences Inc insider buys or sells NBIX shares.

Notify only if

Operation

Value

Type

News

Receive news related to NEUROCRINE BIOSCIENCES INC

Track Activities on NBIX

Account